Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1251097 | 0.86 | APLNR (0.35) | ATMAPLNRGRM2GRM3KMT2A | |
| SCHEMBL1251101 | 0.86 | APLNR (0.35) | ATMAPLNRGRM2GRM3KMT2A | |
| SCHEMBL1251099 | 0.86 | APLNR (0.35) | ATMAPLNRGRM2GRM3KMT2A | |
| SCHEMBL19075644 | 0.80 | RIPK1 (0.34) | APLNRGRM2GRM3KMT2A | |
| SCHEMBL19083941 | 0.77 | ATM (0.43) | ATMGRM2GRM3POLBCNR2 | |
| SCHEMBL17428797 | 0.77 | ATM (0.43) | ATMAPLNRSMN1; SMN2GRM2GRM3 | |
| SCHEMBL789367 | 0.76 | HSD17B10 (0.41) | SMN1; SMN2 | |
| SCHEMBL19388647 | 0.76 | HSD17B10 (0.41) | SMN1; SMN2 | |
| SCHEMBL1509061 | 0.76 | HSD17B10 (0.41) | SMN1; SMN2 | |
| SCHEMBL19131391 | 0.76 | HSD17B10 (0.41) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885APLNR 1838/4885SMN1; SMN2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.